DDInter1650 DDInter1628
Secobarbital (marketed by Eli Lilly and Company under the brand names Seconal and Tuinal) is a barbiturate derivative drug with anaesthetic, anticonvulsant, sedative and hypnotic properties. It is commonly known as quinalbarbitone in the United Kingdom.
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Secobarbital {u} (Compound) causes {v} (Side Effect) Headache
Headache {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Secobarbital {u} (Compound) resembles {v} (Compound) Amobarbital
Amobarbital {u} (Compound) causes {v} (Side Effect) Headache
Headache {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Secobarbital {u} (Compound) resembles {v} (Compound) Pentobarbital
Pentobarbital {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Secobarbital {u} (Compound) resembles {v} (Compound) Pentobarbital
Pentobarbital {u} (Compound) downregulates {v} (Gene) BRCA1
BRCA1 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Secobarbital {u} (Compound) resembles {v} (Compound) Thiopental
Thiopental {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Secobarbital {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) interacts with {v} (Gene) MAST1
MAST1 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Secobarbital {u} (Compound) binds {v} (Gene) GABRA1
GABRA1 {u} (Gene) regulates {v} (Gene) DERA
DERA {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Secobarbital {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lidocaine
Lidocaine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Secobarbital {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bortezomib
Bortezomib {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Secobarbital {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lidocaine
Lidocaine {u} (Compound) causes {v} (Side Effect) Headache
Headache {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Secobarbital (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ruxolitinib (Compound)
Secobarbital (Compound) resembles Amobarbital (Compound) and Amobarbital (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ruxolitinib (Compound)
Secobarbital (Compound) resembles Pentobarbital (Compound) and Pentobarbital (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Secobarbital (Compound) resembles Pentobarbital (Compound) and Pentobarbital (Compound) downregulates BRCA1 (Gene) and BRCA1 (Gene) is downregulated by Ruxolitinib (Compound)
Secobarbital (Compound) resembles Thiopental (Compound) and Thiopental (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Secobarbital (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) interacts with MAST1 (Gene) and MAST1 (Gene) is bound by Ruxolitinib (Compound)
Secobarbital (Compound) binds GABRA1 (Gene) and GABRA1 (Gene) regulates DERA (Gene) and DERA (Gene) is downregulated by Ruxolitinib (Compound)
Secobarbital may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Secobarbital may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)
Secobarbital may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ruxolitinib (Compound)